Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTRIVA
2023-509391-42-00Phase 4Authorised
- Sponsor
- Takeda
- Start
- Jun 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 4, randomised, double-blind trial of vedolizumab and upadacitinib in Crohn's disease (2 arms), sponsored by Takeda. Primary endpoints: CDAI-defined clinical remission at Week 12 and Endoscopic response at Week 12. Planned start Jun 2025; status: authorised.
02
Drugs
vedolizumabupadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-509391-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509391-42-00.